Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964.
No abstract available

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Chlorambucil / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Chlorambucil
  • obinutuzumab